Compare Motorola Solutions Inc (MSI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Sanofi SA — how do they compare? Motorola Solutions Inc trades at $467.99 (market cap $77.26B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| MSI | SNY | |
|---|---|---|
Market Cap | $77.26B | $104.30B |
Sector | Technology | Health |
52-Week High | $490.30 | $52.34 |
52-Week Low | $363.83 | $41.33 |
Enterprise Value | $86.17B | $124.19B |
Dividend Yield | 1.04% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $461.98, down 1.19% today but has demonstrated strong momentum with three consecutive quarterly earnings beats and a 23.5% gain over three months. The company reported record Q2 2026 results with 13% revenue growth and raised full-year guidance, supported by a record $15.6 billion backlog. Technical indicators show a bullish trend with the stock near its pivot point of $463, while valuation metrics remain elevated with a P/E of 36.79.
The outlook remains positive given strong demand in public safety communications and software services, with analyst consensus pointing to 15% upside to the $533.80 price target. Key risks include execution challenges to meet elevated expectations and the premium valuation requiring sustained high growth. The combination of operational strength and bullish sentiment supports a constructive view for investors.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
